Skip to content

Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)

Investigation of the Likelihood of a Current Major Depressive Episode in Individuals Referred to Sleep Clinics for Polysomnography (PSG) Assessment Using the MEB-001 Device.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05708222
Acronym
SAMDE
Enrollment
715
Registered
2023-02-01
Start date
2022-09-01
Completion date
2024-07-09
Last updated
2024-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression, Depression Mild, Depressive Disorder, Depressive Disorder, Major, Depressive Episode

Keywords

Major Depressive Episodes, Depression, Sleep Study

Brief summary

The objective of this study is to collect data to finalize the development of MEB-001 software as a medical device. The data collected in this study will be used to develop MEB-001 machine learning algorithms by training the algorithms to match the patient's demographic and clinical information, and the objective physiological signals (i.e., electroencephalogram (EEG) and electrocardiogram (ECG)) recorded during PSG with the diagnosis of cMDE performed through the MINI neuropsychiatric evaluation.

Detailed description

This is a two (2)-phase, single-arm, prospective, non-significant risk, multi-center trial where each enrolled subject's data will be used for the development of MEB-001. Study Population: Subjects who are at least 22 years old but not older than 75 years old, who have been referred to a sleep clinic for sleep disturbances and sign an informed consent form (ICF) will be evaluated for participation in this study. The selection of the population involved in the study will consider the geographic diversity needed to obtain a representative sample of the intended use population. Centers will be selected to secure geographic and clinical diversity across the USA to obtain a representative distribution of the intended patient population. All patients undergoing PSG due to primary or secondary sleep disorders, which include, but are not limited to, Sleep-Related Movement Disorders, Sleep-Related Breathing Disorders, Intrinsic and Extrinsic Circadian Rhythm Sleep-Wake Disorders, Hypersomnia, Parasomnia, and Insomnia, will be consecutively recruited, according to the inclusion/exclusion criteria.

Interventions

DEVICEMEB-001

The study is for the development of a software medical device. The study participant will complete study specific questionnaires and undergo a routine sleep study. The medical device will not provide any treatment or interventions.

Sponsors

Medibio Limited
Lead SponsorINDUSTRY

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
22 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

Subjects must meet ALL the following conditions to be eligible to participate in the study: 1. Subject is age ≥ 22 years and ≤ 75 years. 2. Subject is undergoing polysomnography due to suspected primary or secondary sleep disorders. 3. Subject is willing and able to provide informed consent. 4. Subject has the ability to read and understand the instructions for the study. 5. Subject is willing to adhere to study procedures. 6. Subject is willing to undergo full night diagnostic PSG study, as prescribed.

Exclusion criteria

Subjects will not be eligible, and they will not be recruited to participate in the study if any of the following conditions are present: 1. Subject has a pacemaker. 2. Subject has undergone a heart transplant. 3. Subject is undergoing a full night C-PAP titration study.

Design outcomes

Primary

MeasureTime frameDescription
Development of software as a medical device for the assessment of current major depressive episodes.24 monthsEvaluation of patient objective and subjective measures to develop algorithm to determine whether the patient is experiencing a current major depressive episode.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026